Literature DB >> 11724919

Progressive supranuclear palsy.

K Tawana1, D B Ramsden.   

Abstract

This review concentrates on the molecular pathology of the protein tau, including its expression in various regions of the brain. The role of post-translational modifications in fibrillogenesis is also discussed, particularly hyperphosphorylation and glycation. However, the initiating event that causes aberrant tau processing remains unclear.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11724919      PMCID： PMC1187134     

Source DB:  PubMed          Journal:  Mol Pathol        ISSN： 1366-8714


  66 in total

Review 1.  Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17.

Authors:  S H Yen; M Hutton; M DeTure; L W Ko; P Nacharaju
Journal:  Brain Pathol       Date:  1999-10       Impact factor: 6.508

2.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

3.  Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease.

Authors:  M A Norlund; J M Lee; G M Zainelli; N A Muma
Journal:  Brain Res       Date:  1999-12-18       Impact factor: 3.252

4.  Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations.

Authors:  P M Stanford; G M Halliday; W S Brooks; J B Kwok; C E Storey; H Creasey; J G Morris; M J Fulham; P R Schofield
Journal:  Brain       Date:  2000-05       Impact factor: 13.501

5.  Modulation of tau phosphorylation and intracellular localization by cellular stress.

Authors:  S M Jenkins; M Zinnerman; C Garner; G V Johnson
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

6.  Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.

Authors:  J Tucholski; J Kuret; G V Johnson
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

7.  Clinical genetics of familial progressive supranuclear palsy.

Authors:  A Rojo; R S Pernaute; A Fontán; P G Ruíz; J Honnorat; T Lynch; S Chin; I Gonzalo; A Rábano; A Martínez; S Daniel; P Pramstaller; H Morris; N Wood; A Lees; C Tabernero; T Nyggard; A C Jackson; A Hanson; J G de Yébenes; P Pramsteller
Journal:  Brain       Date:  1999-07       Impact factor: 13.501

8.  Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein.

Authors:  J Fergusson; M Landon; J Lowe; L Ward; F W van Leeuwen; R J Mayer
Journal:  Neurosci Lett       Date:  2000-01-28       Impact factor: 3.046

Review 9.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.

Authors:  D W Dickson
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

Review 10.  Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease.

Authors:  L Buée; A Delacourte
Journal:  Brain Pathol       Date:  1999-10       Impact factor: 6.508
View more
  8 in total

1.  Tau isoforms expression in transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Ewa Usarek; Magdalena Kuźma-Kozakiewicz; Birgit Schwalenstöcker; Beata Kaźmierczak; Christoph Münch; Albert C Ludolph; Anna Barańczyk-Kuźma
Journal:  Neurochem Res       Date:  2006-05-23       Impact factor: 3.996

2.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

3.  Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Authors:  Hye-Jin Park; Kang-Woo Lee; Stephanie Oh; Run Yan; Jie Zhang; Thomas G Beach; Charles H Adler; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

4.  Repetitive finger movement performance differs among Parkinson's disease, Progressive Supranuclear Palsy, and spinocerebellar ataxia.

Authors:  Elizabeth L Stegemöller; Jennifer Uzochukwu; Mark D Tillman; Nikolaus R McFarland; S H Subramony; Michael S Okun; Chris J Hass
Journal:  J Clin Mov Disord       Date:  2015-02-16

Review 5.  Imaging tau pathology in Parkinsonisms.

Authors:  Sarah Coakeley; Antonio P Strafella
Journal:  NPJ Parkinsons Dis       Date:  2017-06-29

6.  Increased prefrontal cortex interleukin-2 protein levels and shift in the peripheral T cell population in progressive supranuclear palsy patients.

Authors:  Rasmus Rydbirk; Betina Elfving; Jonas Folke; Bente Pakkenberg; Kristian Winge; Tomasz Brudek; Susana Aznar
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

7.  Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality.

Authors:  Kyung-Hyun Cho; Ji-Eun Kim; Hyo-Seon Nam; Dae-Jin Kang; Hye-Jee Na
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

Review 8.  Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.

Authors:  Ruth Lamb; Jonathan D Rohrer; Andrew J Lees; Huw R Morris
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.